AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
VistaGen Therapeutics, Inc.
Video analysis: VTGN
All videosNo video analysis for this stock yet. Request one from our team.
News: VTGN
Vistagen to Present at Psych Congress 2026
Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder.
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines.
Vistagen Appoints Douglas J. Williamson to its Board of Directors
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population.
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder. PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase.
